Neovacs S.A. | Ownership

Companies that own Neovacs S.A.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Gestys SA
350,000
0.38%
50,000
2.02%
03/23/2018
Friedland Gestion SAS
77,856
0.09%
0
0.23%
09/29/2017
Allianz Global Investors GmbH (France)
6,182
0.01%
412
0%
12/31/2015
Perinvest (UK) Ltd.
0
0%
-373,598
0%
06/30/2017
CM-CIC Asset Management SA
0
0%
-57,214
0%
06/30/2017

About Neovacs

View Profile
Address
3-5, Impasse Reille
Paris Ile-de-France 75014
France
Employees -
Website http://www.neovacs.fr
Updated 07/08/2019
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases. It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and Interferon-Kinoid for treating lupus. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.